Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raquel de Paz

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Annals of Hematology|September 13, 2024
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminibLucía Pérez-Lamas, Adrián Segura Díaz, Elvira Mora Casterá, et al.
Genes, Chromosomes & Cancer|October 15, 2013
Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testingLeonor Arenillas, Mar Mallo, Fernando Ramos, et al.
Expert Review of Hematology|December 7, 2020
Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in MadridPaula Lázaro Del Campo, Andrés Ramírez López, Beatriz de la Cruz Benito, et al.
Annals of Internal Medicine|February 21, 2018
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label StudyFrançois-Xavier Mahon, Carla Boquimpani, Dong-Wook Kim, et al.
Plos One|June 13, 2015
Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?Sílvia Saumell, Francesc Solé, Leonor Arenillas, et al.
Leukemia Research Reports|October 27, 2015
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinationsAurelio Lopez, Maria-Victoria Mateos, Albert Oriol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myelomaBruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
British Journal of Haematology|November 30, 2025
Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trialRami S Komrokji, Valeria Santini, Uwe Platzbecker, et al.
British Journal of Haematology|April 11, 2014
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletionJoaquín Sánchez-García, Consuelo Del Cañizo, Ignacio Lorenzo, et al.
Annals of Hematology|January 20, 2026
One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with ImatinibLucía Pérez-Lamas, Mario Manzanares, Juan Carlos Hernández Boluda, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Annals of Hematology|September 13, 2024
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminibLucía Pérez-Lamas, Adrián Segura Díaz, Elvira Mora Casterá, et al.
Genes, Chromosomes & Cancer|October 15, 2013
Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testingLeonor Arenillas, Mar Mallo, Fernando Ramos, et al.
Expert Review of Hematology|December 7, 2020
Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in MadridPaula Lázaro Del Campo, Andrés Ramírez López, Beatriz de la Cruz Benito, et al.
Annals of Internal Medicine|February 21, 2018
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label StudyFrançois-Xavier Mahon, Carla Boquimpani, Dong-Wook Kim, et al.
Plos One|June 13, 2015
Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?Sílvia Saumell, Francesc Solé, Leonor Arenillas, et al.
Leukemia Research Reports|October 27, 2015
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinationsAurelio Lopez, Maria-Victoria Mateos, Albert Oriol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myelomaBruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
British Journal of Haematology|November 30, 2025
Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trialRami S Komrokji, Valeria Santini, Uwe Platzbecker, et al.
British Journal of Haematology|April 11, 2014
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletionJoaquín Sánchez-García, Consuelo Del Cañizo, Ignacio Lorenzo, et al.
Annals of Hematology|January 20, 2026
One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with ImatinibLucía Pérez-Lamas, Mario Manzanares, Juan Carlos Hernández Boluda, et al.
Pageof 7